☰

Lucy A. Godley - Publications

Affiliations: 
Cancer Biology University of Chicago, Chicago, IL 
Area:
Oncology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

181/313 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Stubbins RJ, Korotev S, Godley LA. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies. Current Hematologic Malignancy Reports. PMID 35674998 DOI: 10.1007/s11899-022-00663-7  0.319
2021 Samra N, Toubiana S, Yttervik H, Tzur-Gilat A, Morani I, Itzkovich C, Giladi L, Abu Jabal K, Cao JZ, Godley LA, Mory A, Baris Feldman H, Tveten K, Selig S, Weiss K. RBL2 bi-allelic truncating variants cause severe motor and cognitive impairment without evidence for abnormalities in DNA methylation or telomeric function. Journal of Human Genetics. PMID 33980986 DOI: 10.1038/s10038-021-00931-z  0.328
2020 Toubiana S, Larom G, Smoom R, Duszynski RJ, Godley LA, Francastel C, Velasco G, Selig S. Regulation of telomeric function by DNA methylation differs between humans and mice. Human Molecular Genetics. PMID 32916696 DOI: 10.1093/Hmg/Ddaa206  0.409
2020 Cao JZ, Liu H, Wickrema A, Godley LA. HIF-1 directly induces TET3 expression to enhance 5-hmC density and induce erythroid gene expression in hypoxia. Blood Advances. 4: 3053-3062. PMID 32634239 DOI: 10.1182/Bloodadvances.2020001535  0.388
2020 Kewan T, Noss R, Godley LA, Rogers HJ, Carraway HE. Inherited Thrombocytopenia Caused by Germline Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome. Journal of Investigative Medicine High Impact Case Reports. 8: 2324709620938941. PMID 32618208 DOI: 10.1177/2324709620938941  0.339
2020 Brown AL, Arts P, Carmichael CL, Babic M, Dobbins J, Chong CE, Schreiber AW, Feng J, Phillips K, Wang PPS, Ha T, Homan CC, King-Smith SL, Rawlings L, Vakulin C, ... ... Godley LA, et al. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances. 4: 1131-1144. PMID 32208489 DOI: 10.1182/Bloodadvances.2019000901  0.358
2020 Wu D, Luo X, Feurstein S, Kesserwan C, Mohan S, Pineda-Alvarez DE, Godley LA. How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies. Haematologica. PMID 32165484 DOI: 10.3324/Haematol.2018.214221  0.323
2020 Qiu Z, Lin AP, Jiang S, Elkashef SM, Myers J, Srikantan S, Sasi B, Cao JZ, Godley LA, Rakheja D, Lyu Y, Zheng S, Madesh M, Shiio Y, Dahia PLM, et al. MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell Chemical Biology. PMID 32101699 DOI: 10.1016/J.Chembiol.2020.02.002  0.33
2020 Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, et al. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Advances. 4: 599-606. PMID 32074275 DOI: 10.1182/Bloodadvances.2019000795  0.305
2020 Kraft IL, Trottier AM, Steinhardt GF, Niu N, Wanjari P, Chen W, Segal J, Godley LA. Using sequential next-generation sequencing assays to identify germline cancer predisposition variants. Journal of Clinical Oncology. 38: 1581-1581. DOI: 10.1200/Jco.2020.38.15_Suppl.1581  0.337
2019 Applebaum MA, Barr EK, Karpus J, West-Szymanski DC, Oliva M, Sokol EA, Zhang S, Zhang Z, Zhang W, Chlenksi A, Salwen HR, Wilkinson E, Dobratic M, Grossman RL, Godley LA, et al. 5-hydroxymethylcytosine profiles in circulating cell-free DNA associate with disease burden in children with neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31852832 DOI: 10.1158/1078-0432.Ccr-19-2829  0.388
2019 Luo X, Feurstein S, Mohan S, Porter CC, Jackson SA, Keel S, Chicka M, Brown AL, Kesserwan C, Agarwal A, Luo M, Li Z, Ross JE, Baliakas P, Pineda-Alvarez D, ... ... Godley LA, et al. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Advances. 3: 2962-2979. PMID 31648317 DOI: 10.1182/Bloodadvances.2019000644  0.355
2019 Godley LA. Inherited predisposition to myeloid malignancies. Blood Advances. 3: 2688. PMID 31506287 DOI: 10.1182/Bloodadvances.2019000172  0.333
2019 Godley LA. FouNdER mutations confer risk for leukemias. Blood. 133: 2636-2638. PMID 31221794 DOI: 10.1182/Blood-2019-04-901173  0.306
2019 Trottier AM, Cavalcante de Andrade Silva M, Li Z, Godley LA. Somatic mutation panels: Time to clear their names. Cancer Genetics. PMID 31101556 DOI: 10.1016/J.Cancergen.2019.04.065  0.37
2019 Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, ... ... Godley LA, et al. Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis. Cancer Discovery. PMID 30944118 DOI: 10.1158/2159-8290.Cd-18-1138  0.376
2019 Trottier AM, Kraft IL, Druhan LJ, Lance A, Avalos BR, Godley LA. New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies Blood. 134: 2543-2543. DOI: 10.1182/Blood-2019-129492  0.324
2019 Singhal D, Hahn CN, Moma LD, Wee LYA, Chhetri R, Babic M, Kutyna MM, Hiwase S, Parker WT, Feng J, Schreiber AW, Geoghegan J, Arts P, Gowda R, Singhal N, ... ... Godley LA, et al. Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy Blood. 134: 1704-1704. DOI: 10.1182/Blood-2019-126462  0.36
2019 Kosuri S, Lee SM, Liu H, Mortel M, Godley LA, Larson RA, Odenike O, Stock W, Kline J, Riedell PA, Van Besien K, Bishop MR, Artz AS. Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS Blood. 134: 3324-3324. DOI: 10.1182/Blood-2019-126211  0.306
2018 Obrochta E, Godley LA. Identifying patients with genetic predisposition to acute myeloid leukemia. Best Practice & Research. Clinical Haematology. 31: 373-378. PMID 30466750 DOI: 10.1016/J.Beha.2018.09.014  0.399
2018 Busque L, Godley LA. : guardian of the epigenetic galaxy. Blood. 132: 1468-1469. PMID 30287469 DOI: 10.1182/Blood-2018-08-867044  0.361
2018 D'Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz AS. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leukemia & Lymphoma. 1-10. PMID 30070150 DOI: 10.1080/10428194.2018.1493728  0.342
2018 Meisel M, Hinterleitner R, Pacis A, Chen L, Earley ZM, Mayassi T, Pierre JF, Ernest JD, Galipeau HJ, Thuille N, Bouziat R, Buscarlet M, Ringus DL, Wang Y, Li Y, ... ... Godley LA, et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. PMID 29769727 DOI: 10.1038/S41586-018-0125-Z  0.328
2018 Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, ... ... Godley LA, et al. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. Cancer Research. PMID 29559475 DOI: 10.1158/0008-5472.Can-17-1900  0.424
2018 Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, Calderon DA, Jones MF, Weipert CM, Daugherty CK, Ceballos-López AA, Raca G, Lingen MW, Li Z, Segal JP, ... ... Godley LA, et al. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Advances. 2: 146-150. PMID 29365323 DOI: 10.1182/Bloodadvances.2017013037  0.337
2018 Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek JE, Curran E, Pettit K, et al. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. Journal of Hematology & Oncology. 11: 4. PMID 29304833 DOI: 10.1186/S13045-017-0550-8  0.319
2018 Wang A, Weiner H, Larson RA, Odenike O, Artz AS, Bishop MR, Godley L, Thirman M, Kosuri S, Churpek J, Curran EK, Pettit K, Stock W, Liu H. Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Blood. 132: 4073-4073. DOI: 10.1182/Blood-2018-99-120244  0.302
2018 Godley L, Luo X, Ross J, Jackson S, Agarwal A, Baliakas P, Bertuch AA, Brown AL, Chicka MC, DiNardo CD, Fleming MD, Keel S, Kesserwan C, Li Z, Luo M, et al. Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms Blood. 132: 5849-5849. DOI: 10.1182/Blood-2018-99-118979  0.32
2017 Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, et al. Reduced Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared to Matched Unrelated Donor Stem Cells in Older Adults. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29288821 DOI: 10.1016/J.Bbmt.2017.12.794  0.307
2017 Desai AV, Perpich M, Godley LA. Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience. Frontiers in Pediatrics. 5: 252. PMID 29270394 DOI: 10.3389/Fped.2017.00252  0.331
2017 Godley LA. Mutant RUNX1 and histone tales. Blood. 130: 2156-2157. PMID 29146818 DOI: 10.1182/Blood-2017-09-805382  0.349
2017 Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, et al. Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Research. PMID 28986391 DOI: 10.1101/Gr.222794.117  0.395
2017 Brown AL, Churpek JE, Malcovati L, Döhner H, Godley LA. Recognition of familial myeloid neoplasia in adults. Seminars in Hematology. 54: 60-68. PMID 28637618 DOI: 10.1053/J.Seminhematol.2016.11.003  0.327
2017 Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. PMID 28600339 DOI: 10.1182/Blood-2017-02-735290  0.32
2017 Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. International Journal of Hematology. PMID 28555414 DOI: 10.1007/S12185-017-2259-4  0.372
2017 Godley LA. DNAJC21: the new kid on the SDS block. Blood. 129: 1413-1414. PMID 28302692 DOI: 10.1182/Blood-2017-01-761635  0.342
2017 Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock W. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leukemia & Lymphoma. 1-7. PMID 28278716 DOI: 10.1080/10428194.2017.1289524  0.323
2017 Godley LA. Abstract IA15: Genetic predisposition to hematopoietic malignancies Genomics. 23. DOI: 10.1158/1557-3265.Hemmal17-Ia15  0.383
2016 Feurstein S, Drazer MW, Godley LA. Genetic predisposition to leukemia and other hematologic malignancies. Seminars in Oncology. 43: 598-608. PMID 27899193 DOI: 10.1053/J.Seminoncol.2016.10.003  0.31
2016 Applebaum MA, Jha AR, Kao C, Hernandez KM, DeWane G, Salwen HR, Chlenski A, Dobratic M, Mariani CJ, Godley LA, Prabhakar N, White K, Stranger BE, Cohn SL. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget. PMID 27765905 DOI: 10.18632/Oncotarget.12713  0.387
2016 Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, van Besien K, Larson RA, Lee MK, Segal JP, King MC, Walsh T, Shimamura A, Keel SB, Churpek JE, ... Godley LA, et al. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27497531 DOI: 10.1016/j.bbmt.2016.08.002  0.355
2016 DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, ... ... Godley LA, et al. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clinical Lymphoma, Myeloma & Leukemia. PMID 27210295 DOI: 10.1016/J.Clml.2016.04.001  0.311
2016 Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, et al. Frequency and Risk Factors Associated with Cord Graft Failure (CGF) after Transplant with Single Unit Umbilical Cord Cells Supplemented by Haploidentical Cells (Haplo-Cord) with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26912055 DOI: 10.1016/J.Bbmt.2016.02.010  0.312
2016 Schulze I, Rohde C, Scheller-Wendorff M, Bäumer N, Krause A, Herbst F, Riemke P, Hebestreit K, Tschanter P, Lin Q, Linhart H, Godley LA, Glimm H, Dugas M, Wagner W, et al. Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. Blood. 127: 1575-86. PMID 26729896 DOI: 10.1182/Blood-2015-07-655928  0.443
2016 Leukam M, Kocherginsky M, Godley LA, Kline JP, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz AS. Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors. Journal of Clinical Oncology. 34: e18537-e18537. DOI: 10.1200/Jco.2016.34.15_Suppl.E18537  0.303
2016 Liu H, Artz AS, Kocherginsky M, Larson RA, Odenike O, Kline JP, Godley LA, LaBelle JL, Stock W, Bishop MR. Feasibility of early withdrawal of immunosuppression (WOI) followed by dose escalation of prophylactic donor lymphocyte infusion (pDLI) after T-cell depleted (TCD) matched donor allogeneic hematopoietic cell transplantation (HCT). Journal of Clinical Oncology. 34: 7050-7050. DOI: 10.1200/Jco.2016.34.15_Suppl.7050  0.304
2016 D'Angelo CR, Novitsky B, Lee SM, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz A. Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality Blood. 128: 5844-5844. DOI: 10.1182/Blood.V128.22.5844.5844  0.352
2016 Wang AY, Weiner HL, Green M, Larson RA, Odenike O, Artz A, Godley LA, Thirman MJ, Churpek JE, Curran EK, Pettit K, Stock W, Liu H. Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable Blood. 128: 212-212. DOI: 10.1182/Blood.V128.22.212.212  0.327
2016 Brown AL, Hahn CN, Carmichael C, Wilkins E, Babic M, Chong C, Li X, Michaud J, Cannon P, Poplawski N, Altree M, Phillips K, Jaensch L, Fine M, Schreiber AW, ... ... Godley LA, et al. Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations Blood. 128: 1212-1212. DOI: 10.1182/Blood.V128.22.1212.1212  0.363
2016 Nath A, Wang F, Lenkala D, LaCroix B, Glavin N, Kipping-Johnson K, Geeleher P, Thirman M, Godley L, Raca G, Larson R, RSH. Abstract 2039: Exploring the longitudinal transcriptomic landscape of tyrosine kinase inhibitor treatment response in chronic myeloid leukemia patients Cancer Research. 76: 2039-2039. DOI: 10.1158/1538-7445.Am2016-2039  0.357
2016 Nath A, Wang F, Lenkala D, LaCroix B, Glavin N, Kipping-Johnson K, Geeleher P, Rich E, Thirman M, Godley L, Raca G, Larson R, Huang R. ID: 26: EXPLORING THE LONGITUDINAL TRANSCRIPTOMIC LANDSCAPE OF TYROSINE KINASE INHIBITOR TREATMENT RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS Journal of Investigative Medicine. 64: 935.2-936. DOI: 10.1136/Jim-2016-000120.50  0.35
2016 Drazer M, West A, Sukhanova M, Feurstein S, Jones M, Segal J, Churpeck J, Godley L. Somatic Next Generation Sequencing Panels Identify Potentially Pathogenic Germline Variants in Genes Associated with Hereditary Myeloid Malignancies Clinical Lymphoma, Myeloma & Leukemia. 16. DOI: 10.1016/J.Clml.2016.07.136  0.319
2015 Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK, Schreiber AW, Feng J, Babic M, Chong CE, Lee Y, Yong A, Suthers GK, Poplawski N, Altree M, ... ... Godley LA, et al. Novel germline DDX41 mutations define families with a lower age of MDS/AML onset, and lymphoid malignancies. Blood. PMID 26712909 DOI: 10.1182/Blood-2015-10-676098  0.353
2015 Laukka T, Mariani CJ, Ihantola T, Cao JZ, Hokkanen J, Kaelin WG, Godley LA, Koivunen P. Fumarate and Succinate Regulate Expression of Hypoxia-Inducible Genes via TET Enzymes. The Journal of Biological Chemistry. PMID 26703470 DOI: 10.1074/Jbc.M115.688762  0.421
2015 Vasanthakumar A, Arnovitz S, Marquez R, Lepore J, Rafidi G, Asom A, Weatherly M, Davis EM, Neistadt B, Duszynski R, Vardiman JW, Le Beau MM, Godley LA, Churpek JE. Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. Blood. PMID 26644450 DOI: 10.1182/Blood-2015-03-635599  0.366
2015 Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M, Godley LA, Le Beau MM, Pritchard CC, Walsh T, King MC, Olopade OI, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. PMID 26641009 DOI: 10.1002/Cncr.29615  0.32
2015 Chapman CG, Mariani CJ, Wu F, Meckel K, Butun F, Chuang A, Madzo J, Bissonette MB, Kwon JH, Godley LA. TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. Scientific Reports. 5: 17568. PMID 26631571 DOI: 10.1038/Srep17568  0.395
2015 Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, Miller CA, Shen D, Fulton R, O'Laughlin M, Fronick C, Pusic I, Uy GL, Braunstein EM, Levis M, Ross J, ... ... Godley LA, et al. Genomic analysis of germline and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. PMID 26492932 DOI: 10.1182/Blood-2015-04-641100  0.363
2015 Vasanthakumar A, Zullow H, Lepore JB, Thomas K, Young N, Anastasi J, Reardon CA, Godley LA. Epigenetic Control of Apolipoprotein E Expression Mediates Gender-Specific Hematopoietic Regulation. Stem Cells (Dayton, Ohio). PMID 26417967 DOI: 10.1002/Stem.2214  0.402
2015 Dominguez PM, Teater M, Chambwe N, Kormaksson M, Redmond D, Ishii J, Vuong B, Chaudhuri J, Melnick A, Vasanthakumar A, Godley LA, Papavasiliou FN, Elemento O, Shaknovich R. DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Reports. 12: 2086-98. PMID 26365193 DOI: 10.1016/J.Celrep.2015.08.036  0.394
2015 Moen EL, Litwin E, Arnovitz S, Zhang X, Zhang W, Dolan ME, Godley LA. Characterization of CpG sites that escape methylation on the inactive human X-chromosome. Epigenetics. 10: 810-8. PMID 26178744 DOI: 10.1080/15592294.2015.1069461  0.684
2015 Yamazaki J, Jelinek J, Lu Y, Cesaroni M, Madzo J, Neumann F, He R, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Kantarjian HM, Liang S, Estecio MR, Godley LA, et al. TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor binding sites in chronic myelomonocytic leukemia. Cancer Research. PMID 25972343 DOI: 10.1158/0008-5472.Can-14-0739  0.799
2015 Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, Singh J, Padgett RA, Gu X, Phillips JG, Clemente M, Parker Y, Lindner D, Dienes B, Jankowsky E, ... ... Godley LA, et al. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 27: 658-70. PMID 25920683 DOI: 10.1016/J.Ccell.2015.03.017  0.368
2015 Vasanthakumar A, Godley LA. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genetics. 208: 167-77. PMID 25892122 DOI: 10.1016/J.Cancergen.2015.02.009  0.349
2015 Brambert PR, Kelpsch DJ, Hameed R, Desai CV, Calafiore G, Godley LA, Raimondi SL. DNMT3B7 expression promotes tumor progression to a more aggressive phenotype in breast cancer cells. Plos One. 10: e0117310. PMID 25607950 DOI: 10.1371/Journal.Pone.0117310  0.392
2015 Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR, Gulsuner S, Pritchard CC, Sanchez-Bonilla M, Delrow JJ, Basom RS, Forouhar M, Gyurkocza B, Schwartz BS, Neistadt B, ... ... Godley LA, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nature Genetics. 47: 180-5. PMID 25581430 DOI: 10.1038/Ng.3177  0.391
2015 Moen EL, Mariani CJ, Zullow H, Jeff-Eke M, Litwin E, Nikitas JN, Godley LA. New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine. Immunological Reviews. 263: 36-49. PMID 25510270 DOI: 10.1111/Imr.12242  0.677
2015 Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational New Drugs. 33: 371-9. PMID 25483416 DOI: 10.1007/S10637-014-0194-2  0.303
2015 Knight Johnson AE, Guidugli L, Arndt K, Alkorta-Aranburu G, Nelakuditi V, Churpek JE, Godley LA, del Gaudio D, Das S, Li Z. Identification of Genetic Hereditary Predisposition to Hematologic Malignancies By Clinical Next-Generation Sequencing Blood. 126: 3854-3854. DOI: 10.1182/Blood.V126.23.3854.3854  0.379
2015 Hantel A, Khan N, Larson RA, Godley LA, Thirman MJ, Artz A, Odenike O, Liu H, Churpek JE, King D, Rich E, Choi KJ, Knoebel RW, Stock W. Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML) Blood. 126: 2518-2518. DOI: 10.1182/Blood.V126.23.2518.2518  0.33
2014 Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, ... ... Godley LA, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Reports. 9: 1841-55. PMID 25482556 DOI: 10.1016/J.Celrep.2014.11.004  0.425
2014 Godley LA. Inherited predisposition to acute myeloid leukemia. Seminars in Hematology. 51: 306-21. PMID 25311743 DOI: 10.1053/J.Seminhematol.2014.08.001  0.318
2014 Zhang X, Moen EL, Liu C, Mu W, Gamazon ER, Delaney SM, Wing C, Godley LA, Dolan ME, Zhang W. Linking the genetic architecture of cytosine modifications with human complex traits. Human Molecular Genetics. 23: 5893-905. PMID 24943591 DOI: 10.1093/Hmg/Ddu313  0.681
2014 Jasielec J, Saloura V, Godley LA. The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia. 28: 1765-73. PMID 24913729 DOI: 10.1038/Leu.2014.163  0.408
2014 Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger RH, Cohn SL, Nanduri J, Verma A, Prabhakar NR, Godley LA. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Reports. 7: 1343-52. PMID 24835990 DOI: 10.1016/J.Celrep.2014.04.040  0.337
2014 Vasanthakumar A, Godley LA. On the origin of leukemic species. Cell Stem Cell. 14: 421-2. PMID 24702991 DOI: 10.1016/J.Stem.2014.03.008  0.338
2014 Marquez R, Hantel A, Lorenz R, Neistadt B, Wong J, Churpek JE, Mardini NA, Shaukat I, Gurbuxani S, Miller JL, Godley LA. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leukemia & Lymphoma. 55: 2945-6. PMID 24628296 DOI: 10.3109/10428194.2014.903476  0.336
2014 Moen EL, Stark AL, Zhang W, Dolan ME, Godley LA. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Molecular Cancer Therapeutics. 13: 1334-44. PMID 24568970 DOI: 10.1158/1535-7163.Mct-13-0924  0.71
2014 West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Annals of the New York Academy of Sciences. 1310: 111-8. PMID 24467820 DOI: 10.1111/Nyas.12346  0.325
2014 Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, Melnick A, Campagne F, Shaknovich R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 123: 1699-708. PMID 24385541 DOI: 10.1182/Blood-2013-07-509885  0.397
2014 Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, ... ... Godley LA, et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Reports. 6: 231-44. PMID 24373966 DOI: 10.1016/J.Celrep.2013.11.044  0.363
2014 Jeong M, Sun D, Luo M, Huang Y, Challen GA, Rodriguez B, Zhang X, Chavez L, Wang H, Hannah R, Kim SB, Yang L, Ko M, Chen R, Göttgens B, ... ... Godley LA, et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nature Genetics. 46: 17-23. PMID 24270360 DOI: 10.1038/Ng.2836  0.442
2014 Tsai SB, Liu H, Shore TB, Bishop MR, Cushing MM, Fan Y, Gergis U, Godley LA, Kline J, Larson RA, Martinez GG, Mayer S, Odenike O, Stock W, Wickrema A, et al. Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation Blood. 124: 2463-2463. DOI: 10.1182/Blood.V124.21.2463.2463  0.3
2014 Rhodes J, van Besien K, Liu H, Gergis U, Tsai SB, Mayer S, Stock W, Larson RA, Shore TB, Odenike O, Pearse R, Godley LA, Mark TM, Kline J, Bishop MR, et al. Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50 Blood. 124: 1235-1235. DOI: 10.1182/Blood.V124.21.1235.1235  0.305
2014 van Besien K, Liu H, Gergis U, Cushing MM, Tsai S, Mayer S, Wickrema A, Stock W, Larson RA, Shore TB, Odenike O, Pearse RN, Godley LA, Mark TM, Kline J, et al. Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study Blood. 124: 1093-1093. DOI: 10.1182/Blood.V124.21.1093.1093  0.309
2014 Moen EL, Stark AL, Zhang W, Dolan ME, Godley LA. Abstract 5461: The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide Cancer Research. 74: 5461-5461. DOI: 10.1158/1538-7445.Am2014-5461  0.439
2013 Mariani CJ, Madzo J, Moen EL, Yesilkanal A, Godley LA. Alterations of 5-hydroxymethylcytosine in human cancers. Cancers. 5: 786-814. PMID 24202321 DOI: 10.3390/Cancers5030786  0.672
2013 Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, ... Godley LA, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discovery. 3: 1002-19. PMID 23955273 DOI: 10.1158/2159-8290.Cd-13-0117  0.411
2013 Nickels EM, Soodalter J, Churpek JE, Godley LA. Recognizing familial myeloid leukemia in adults. Therapeutic Advances in Hematology. 4: 254-69. PMID 23926458 DOI: 10.1177/2040620713487399  0.32
2013 Bhattacharyya S, Yu Y, Suzuki M, Campbell N, Mazdo J, Vasanthakumar A, Bhagat TD, Nischal S, Christopeit M, Parekh S, Steidl U, Godley L, Maitra A, Greally JM, Verma A. Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Research. 41: e157. PMID 23861445 DOI: 10.1093/Nar/Gkt601  0.382
2013 Moen EL, Zhang X, Mu W, Delaney SM, Wing C, McQuade J, Myers J, Godley LA, Dolan ME, Zhang W. Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics. 194: 987-96. PMID 23792949 DOI: 10.1534/Genetics.113.151381  0.673
2013 Goodell MA, Godley LA. Perspectives and future directions for epigenetics in hematology. Blood. 121: 5131-7. PMID 23692857 DOI: 10.1182/Blood-2013-04-427724  0.373
2013 Madzo J, Vasanthakumar A, Godley LA. Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. Seminars in Hematology. 50: 61-9. PMID 23507484 DOI: 10.1053/J.Seminhematol.2013.01.004  0.353
2013 Lu Z, Tian Y, Salwen HR, Chlenski A, Godley LA, Raj JU, Yang Q. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells. Anti-Cancer Drugs. 24: 484-93. PMID 23466651 DOI: 10.1097/Cad.0B013E32835Ffdbb  0.403
2013 Vasanthakumar A, Lepore JB, Zegarek MH, Kocherginsky M, Singh M, Davis EM, Link PA, Anastasi J, Le Beau MM, Karpf AR, Godley LA. Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis. Blood. 121: 2059-63. PMID 23315164 DOI: 10.1182/Blood-2012-04-421065  0.413
2013 Yu Y, Mo Y, Ebenezer D, Bhattacharyya S, Liu H, Sundaravel S, Giricz O, Wontakal S, Cartier J, Caces B, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, ... ... Godley L, et al. High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis. The Journal of Biological Chemistry. 288: 8805-14. PMID 23306203 DOI: 10.1074/Jbc.M112.423756  0.408
2013 Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, et al. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leukemia & Lymphoma. 54: 1242-9. PMID 23088744 DOI: 10.3109/10428194.2012.739688  0.319
2013 Pollyea DA, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, Straley K, Vasanthakumar A, Abdel-Wahab O, Levine R, Godley LA, Medeiros BC. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leukemia & Lymphoma. 54: 408-10. PMID 22680765 DOI: 10.3109/10428194.2012.701009  0.392
2013 Jeong M, Sun D, Luo M, Huang Y, Ko M, Chavez L, Challen GA, Rodriguez B, Zhang X, Yang L, Wang H, Chen R, Hannah R, Kim S, Lee J, ... ... Godley LA, et al. Large Conserved Domains Of Low DNA Methylation Maintained By 5-Hydroxymethycytosine and Dnmt3a Blood. 122: 2406-2406. DOI: 10.1182/Blood.V122.21.2406.2406  0.466
2013 Ustun C, Reiter A, Scott BL, Nakamura R, Gandhi D, Kreil S, Shanley R, Hogan WJ, Perales M, Shore TB, Baurmann H, Stuart RK, Gruhn B, Doubek M, Hsu JW, ... ... Godley LA, et al. Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis Blood. 122: 2145-2145. DOI: 10.1182/Blood.V122.21.2145.2145  0.364
2013 Vasanthakumar A, Zullow H, Godley LA. Hematopoietic Stem Cell Function Is Regulated By Hormonal and Epigenetic Factors Blood. 122: 1194-1194. DOI: 10.1182/Blood.V122.21.1194.1194  0.391
2013 Bhattacharyya S, Yu Y, Suzuki M, Cambpell N, Mazdo J, Vasantkumar A, Bhagat TD, Nischal S, Steidl U, Godley L, Maitra A, Greally JM, Verma A. Abstract 4231: Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Cancer Research. 73: 4231-4231. DOI: 10.1158/1538-7445.Am2013-4231  0.393
2013 Moen EL, Mu W, Godley LA, Dolan ME, Zhang W. Abstract 2216: The role of cytosine modifications in cellular sensitivity to cytarabine. Cancer Research. 73: 2216-2216. DOI: 10.1158/1538-7445.Am2013-2216  0.372
2012 Moen EL, Godley LA, Zhang W, Dolan ME. Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Medicine. 4: 90. PMID 23199206 DOI: 10.1186/Gm391  0.663
2012 Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, Gonen M, Mason CE, ... ... Godley LA, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics. 44: 1179-81. PMID 23001125 DOI: 10.1038/Ng.2413  0.398
2012 Ostler KR, Yang Q, Looney TJ, Zhang L, Vasanthakumar A, Tian Y, Kocherginsky M, Raimondi SL, DeMaio JG, Salwen HR, Gu S, Chlenski A, Naranjo A, Gill A, Peddinti R, ... ... Godley LA, et al. Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Research. 72: 4714-23. PMID 22815530 DOI: 10.1158/0008-5472.Can-12-0886  0.801
2012 Godley LA. Profiles in leukemia. The New England Journal of Medicine. 366: 1152-3. PMID 22417205 DOI: 10.1056/Nejme1200409  0.367
2012 Godley LA, Le Beau MM. The histone code and treatments for acute myeloid leukemia. The New England Journal of Medicine. 366: 960-1. PMID 22397660 DOI: 10.1056/Nejmcibr1113401  0.363
2012 Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley LA, Issa JP. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 7: 201-7. PMID 22395470 DOI: 10.4161/Epi.7.2.19015  0.801
2012 Nanduri J, Makarenko V, Reddy VD, Yuan G, Pawar A, Wang N, Khan SA, Zhang X, Kinsman B, Peng YJ, Kumar GK, Fox AP, Godley LA, Semenza GL, Prabhakar NR. Epigenetic regulation of hypoxic sensing disrupts cardiorespiratory homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 109: 2515-20. PMID 22232674 DOI: 10.1073/Pnas.1120600109  0.343
2012 Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, Liang S, Lu Y, Darlington GJ, Meissner A, Issa JP, ... Godley LA, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics. 44: 23-31. PMID 22138693 DOI: 10.1038/Ng.1009  0.377
2012 Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, Lingen MW. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 31: 15-24. PMID 22123719 DOI: 10.1097/Pgp.0B013E318220Ba16  0.802
2012 van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 913-21. PMID 22079470 DOI: 10.1016/J.Bbmt.2011.10.041  0.303
2012 Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, et al. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leukemia & Lymphoma. 53: 445-50. PMID 21913806 DOI: 10.3109/10428194.2011.621562  0.31
2012 Halpern AB, Kunnavakkum R, Joseph L, Stock W, Odenike O, Godley LA, Thirman MJ, Artz AS, Sipkins D, Liu H, Raca G, Le Beau MM, Larson RA. Single center experience treating adults with FLT3-mutated acute myeloid leukemia (AML). Journal of Clinical Oncology. 30: 6562-6562. DOI: 10.1200/Jco.2012.30.15_Suppl.6562  0.356
2012 Ruiz MA, Vaitkus K, Vasanthakumar A, Rivers A, Kouznetsova T, DeSimone J, Godley LA, Lavelle D. Dynamic Regulation of 5-Hydroxymethylcytosine At the γ-Globin Promoter During Erythroid Differentiation Blood. 120: 824-824. DOI: 10.1182/Blood.V120.21.824.824  0.373
2012 Moen EL, Mu W, Delaney SM, Wing C, Godley LA, Dolan ME, Zhang W. Abstract 5010: Differences in DNA methylation between the African and European HapMap populations Cancer Research. 72: 5010-5010. DOI: 10.1158/1538-7445.Am2012-5010  0.413
2012 Brambert PR, Rehbein J, Slezak I, Kelpsch DJ, Ostler KR, Godley LA, Raimondi SL. Abstract 1053: DNMT3B7 alters E-cadherin expression and cell proliferation in breast cancer cells Cancer Research. 72: 1053-1053. DOI: 10.1158/1538-7445.Am2012-1053  0.791
2012 Ostler KR, Yang Q, Vasanthakumar A, Zhang L, Looney TJ, Naranjo A, Salwen H, Kocherginsky M, Lahn BT, Cohn SL, Godley LA. Abstract 1040: A truncated DNMT3B protein (DNMT3B7) drives DNA methylation and suppresses growth in human neuroblastoma Cancer Research. 72: 1040-1040. DOI: 10.1158/1538-7445.Am2012-1040  0.806
2011 Szulwach KE, Li X, Li Y, Song CX, Wu H, Dai Q, Irier H, Upadhyay AK, Gearing M, Levey AI, Vasanthakumar A, Godley LA, Chang Q, Cheng X, He C, et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nature Neuroscience. 14: 1607-16. PMID 22037496 DOI: 10.1038/Nn.2959  0.389
2011 Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 118: 6438-45. PMID 21976674 DOI: 10.1182/Blood-2011-08-372508  0.317
2011 Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SN, Weinhold N, Reimers M, Clozel T, Luttrop K, Ekstrom TJ, Frank J, Vasanthakumar A, ... Godley LA, et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 118: 3559-69. PMID 21828137 DOI: 10.1182/Blood-2011-06-357996  0.395
2011 Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, da Costa Reis Monte Mor B, Massé A, Le Couédic JP, Pendino F, Carbonne B, Larghero J, Ravanat JL, Casadevall N, Bernard OA, Droin N, ... ... Godley LA, et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood. 118: 2551-5. PMID 21734233 DOI: 10.1182/Blood-2010-12-324707  0.416
2011 Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 20: 25-38. PMID 21723201 DOI: 10.1016/J.Ccr.2011.06.003  0.407
2011 Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, ... ... Godley LA, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 20: 11-24. PMID 21723200 DOI: 10.1016/J.Ccr.2011.06.001  0.352
2011 Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Seminars in Oncology. 38: 215-24. PMID 21421111 DOI: 10.1053/J.Seminoncol.2011.01.003  0.382
2011 Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock W. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Seminars in Oncology. 38: 196-214. PMID 21421110 DOI: 10.1053/J.Seminoncol.2011.01.010  0.383
2011 Godley LA, Mondragón A. Molecular biology. Preference by exclusion. Science (New York, N.Y.). 331: 1017-8. PMID 21350155 DOI: 10.1126/Science.1202090  0.383
2011 Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K, Karpf AR. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2170-80. PMID 21296871 DOI: 10.1158/1078-0432.Ccr-10-2315  0.778
2011 Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 117: 3294-301. PMID 21270442 DOI: 10.1182/Blood-2010-08-301796  0.313
2011 Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, Li Y, Chen CH, Zhang W, Jian X, Wang J, Zhang L, Looney TJ, Zhang B, Godley LA, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nature Biotechnology. 29: 68-72. PMID 21151123 DOI: 10.1038/Nbt.1732  0.353
2011 Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien K. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leukemia & Lymphoma. 52: 214-22. PMID 21142785 DOI: 10.3109/10428194.2010.538777  0.308
2011 Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen VH, Cunningham JM, Larson RA, Cerro PD, Schroeder L, Pape L, Stock W, Wickrema A, et al. Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies Blood. 118: 830-830. DOI: 10.1182/Blood.V118.21.830.830  0.303
2011 Pollyea DA, Kohrt HE, Zhang B, Zehnder JL, Schenkein DP, Fantin V, Straley K, Vasanthakumar A, Abdel-Wahab O, Levine RL, Godley L, Medeiros BC. 2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels Blood. 118: 2509-2509. DOI: 10.1182/Blood.V118.21.2509.2509  0.364
2011 Vasanthakumar A, Lepore JB, Zegarek MH, Kocherginsky M, Singh M, Godley LA. Myc -Mediated Lymphomagenesis Is Driven by DNA Methylation Changes Induced by DNMT3B7 Expression and Dnmt3b Heterozygosity Blood. 118: 225-225. DOI: 10.1182/Blood.V118.21.225.225  0.446
2011 Van Besien KM, Stock W, Rich ES, Odenike O, Godley L, O'Donnell P, Kline J, Nguyen VH, Cerro PD, Larson RA, Artz A. Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study Blood. 118: 1948-1948. DOI: 10.1182/Blood.V118.21.1948.1948  0.311
2011 Clozel T, Yang S, Kormaksson M, Elstrom R, Vasanthakumar A, Brennan S, Culjkovic B, Leser M, Martin P, Borden KL, Wang YL, Cheng S, Tam W, Shaknovich R, Chadburn A, ... Godley L, et al. Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues Blood. 118: 1617-1617. DOI: 10.1182/Blood.V118.21.1617.1617  0.421
2011 Yamazaki J, Taby RF, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley L, Issa J. Limited Effect of TET2 Mutations on Promoter DNA Methylation in Chronic Myelomonocytic Leukemia Blood. 118: 1365-1365. DOI: 10.1182/Blood.V118.21.1365.1365  0.803
2010 Larson SM, Godley LA. Getting to the root of the stem cell in mutated chronic myeloid leukemia. Leukemia & Lymphoma. 51: 2147-8. PMID 21133735 DOI: 10.3109/10428194.2010.531802  0.345
2010 Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, ... ... Godley LA, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 18: 553-67. PMID 21130701 DOI: 10.1016/J.Ccr.2010.11.015  0.439
2010 Smith SM, Anastasi J, Cohen KS, Godley LA. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells, Molecules & Diseases. 45: 317-23. PMID 20817505 DOI: 10.1016/J.Bcmd.2010.08.002  0.354
2010 Garcia JS, Jain N, Godley LA. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Oncotargets and Therapy. 3: 1-13. PMID 20616953 DOI: 10.2147/Ott.S7222  0.347
2010 Shah MY, Vasanthakumar A, Barnes NY, Figueroa ME, Kamp A, Hendrick C, Ostler KR, Davis EM, Lin S, Anastasi J, Le Beau MM, Moskowitz IP, Melnick A, Pytel P, Godley LA. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Research. 70: 5840-50. PMID 20587527 DOI: 10.1158/0008-5472.CAN-10-0847  0.793
2010 Yang Q, Tian Y, Ostler KR, Chlenski A, Guerrero LJ, Salwen HR, Godley LA, Cohn SL. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. Bmc Cancer. 10: 286. PMID 20546602 DOI: 10.1186/1471-2407-10-286  0.791
2010 Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leukemia & Lymphoma. 51: 995-1006. PMID 20536346 DOI: 10.3109/10428191003763468  0.308
2010 Locke FL, Artz AS, Godley LA, Odenike O, Larson RA, Van Besien K, Stock W. A prospective feasibility study of clofarabine (CLO) cytoreduction prior to allogeneic stem cell transplant (HCT) conditioning for refractory leukemia and MDS. Journal of Clinical Oncology. 28: 6537-6537. DOI: 10.1200/Jco.2010.28.15_Suppl.6537  0.311
2010 Garcia JS, Madzo J, Cooper D, Jackson SA, Onel K, Larson RA, Artz A, Godley LA. Pre-Donor Evaluation of an HLA Matched Sibling Identifies a Novel Inherited RUNX1 Mutation Encoding a Missense Mutation Found Outside of the RUNT Domain in Familial Platelet Disorder Blood. 116: 2709-2709. DOI: 10.1182/Blood.V116.21.2709.2709  0.407
2009 Poiré X, Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien K. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leukemia & Lymphoma. 50: 85-91. PMID 19142796 DOI: 10.1080/10428190802626624  0.322
2009 Shah M, Vasanthakumar A, Barnes N, Godley LA. Expression of a Truncated DNMT3B Protein, DNMT3B7, Highlights the Sensitivity of Hematopoietic Progenitor Cell Function to Hormonal Milieu. Blood. 114: 83-83. DOI: 10.1182/Blood.V114.22.83.83  0.434
2009 Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, et al. Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse. Blood. 114: 788-788. DOI: 10.1182/Blood.V114.22.788.788  0.317
2009 Churpek JE, Garcia JS, Madzo J, Jackson S, Onel K, Godley LA. Molecular Characterization of a Novel 3' Mutation in RUNX1 in a New Pedigree with Familial Platelet Disorder. Blood. 114: 1626-1626. DOI: 10.1182/Blood.V114.22.1626.1626  0.386
2009 Larson S, Campbell N, Huo D, Artz A, Zhang Y, Gajria D, Green M, Rahimova G, Weiner H, Torres M, Odenike O, Godley LA, Rich ES, Thirman M, Larson RA, et al. High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML). Blood. 114: 1048-1048. DOI: 10.1182/Blood.V114.22.1048.1048  0.305
2009 Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, van Besien K, Daugherty C, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of Therapy-Related Myeloid Neoplasms with High-Dose Cytarabine/Mitoxantrone Followed by Hematopoietic Cell Transplantation (HCT). Blood. 114: 1030-1030. DOI: 10.1182/Blood.V114.22.1030.1030  0.312
2008 Godley LA, Steensma DP, Baer MR, Slack JL, Buckstein R, Larsen JS, Arora S, Cullen MT, Kantarjian HM. Cytogenetic responses to a 5-day dosing schedule of decitabine in patients (Pts) with myelodysplastic syndromes (MDS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7030. PMID 27950013 DOI: 10.1200/Jco.2008.26.15_Suppl.7030  0.309
2008 Fackenthal JD, Godley LA. Aberrant RNA splicing and its functional consequences in cancer cells. Disease Models & Mechanisms. 1: 37-42. PMID 19048051 DOI: 10.1242/Dmm.000331  0.389
2008 Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, Rich ES, Stock W, Ulaszek J, Larson RA, van Besien K. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 14: 1209-16. PMID 18940674 DOI: 10.1016/J.Bbmt.2008.08.004  0.307
2008 Carbonaro A, Mohanty SK, Huang H, Godley LA, Sohn LL. Cell characterization using a protein-functionalized pore Lab On a Chip - Miniaturisation For Chemistry and Biology. 8: 1478-1485. PMID 18818802 DOI: 10.1039/B801929K  0.303
2008 Ozer O, Zhao YD, Ostler KR, Akin C, Anastasi J, Vardiman JW, Godley LA. The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells. Leukemia & Lymphoma. 49: 1567-77. PMID 18766971 DOI: 10.1080/10428190802140865  0.792
2008 Godley LA, Larson RA. Therapy-related myeloid leukemia. Seminars in Oncology. 35: 418-29. PMID 18692692 DOI: 10.1053/J.Seminoncol.2008.04.012  0.308
2008 Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2444-9. PMID 18413836 DOI: 10.1158/1078-0432.Ccr-07-1320  0.394
2008 Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, et al. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leukemia & Lymphoma. 49: 531-7. PMID 18297531 DOI: 10.1080/10428190701799043  0.353
2007 Mattison RJ, Ostler KR, Locke FL, Godley LA. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Reviews On Recent Clinical Trials. 2: 135-41. PMID 18473998 DOI: 10.2174/157488707780599320  0.781
2007 Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 40: 1027-32. PMID 17846595 DOI: 10.1038/Sj.Bmt.1705852  0.328
2007 Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematologic malignancies. Leukemia & Lymphoma. 48: 1676-95. PMID 17786703 DOI: 10.1080/10428190701493910  0.376
2007 Ostler KR, Davis EM, Payne SL, Gosalia BB, Expósito-Céspedes J, Le Beau MM, Godley LA. Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene. 26: 5553-63. PMID 17353906 DOI: 10.1038/Sj.Onc.1210351  0.811
2007 Ozer O, Zhao YD, Ostler KR, Akin C, Anastasi J, Vardiman J, Godley L. Novel C-KIT Transcripts Identified in Mast Cell Leukemia: An Update of the Full Transcript and It’s Distribution. Blood. 110: 2396-2396. DOI: 10.1182/Blood.V110.11.2396.2396  0.785
2007 Donepudi S, Mattison RJ, Kihslinger JE, Godley LA. Modulators of DNA methylation and histone acetylation Update On Cancer Therapeutics. 2: 157-169. DOI: 10.1016/J.Uct.2007.10.004  0.399
2006 Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, Van Besien K. New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood. 108: 3675-3675. DOI: 10.1182/Blood.V108.11.3675.3675  0.305
2005 van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5728-38. PMID 16009946 DOI: 10.1200/Jco.2005.15.602  0.305
2005 Pollyea DA, Artz AS, Stock W, Godley L, Odenike OM, Rich E, Smith SM, Larson R, Van Besien K. Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen. Blood. 106: 2022-2022. DOI: 10.1182/Blood.V106.11.2022.2022  0.308
2005 Kline J, Pollyea D, Artz A, Stock W, Rich E, Godley L, Zimmerman T, van Besien K. Ganciclovir and high-dose valacyclovir reduce cytomegalovirus reactivation in patients receiving allogeneic stem cell transplantation with Campath-1H–based conditioning regimens Biology of Blood and Marrow Transplantation. 11: 94. DOI: 10.1016/J.Bbmt.2004.12.277  0.307
2004 van Besien KW, Artz A, Smith S, Rich E, Godley L, Jones D, Cerro PD, Switzer D, Casey B, Odenike O, Thirman M, Daugherty C, Zimmerman TM, Larson R, Stock W. Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden. Blood. 104: 2321-2321. DOI: 10.1182/Blood.V104.11.2321.2321  0.307
2004 Ozer O, Anastasi J, Vardiman JW, Godley LA. Identical Novel C-Kit Transcripts in Two Patients with Mast Cell Leukemia. Blood. 104: 2001-2001. DOI: 10.1182/Blood.V104.11.2001.2001  0.412
2004 Pollyea DA, Artz AS, Stock W, Smith SM, Daugherty C, Godley L, Zimmerman T, Odenike OM, Thirman M, Rich E, Larson R, Van Besien K. Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST). Blood. 104: 1145-1145. DOI: 10.1182/Blood.V104.11.1145.1145  0.307
2002 Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 99: 14925-30. PMID 12417757 DOI: 10.1073/Pnas.222491799  0.402
2001 Lai F, Godley LA, Joslin J, Fernald AA, Liu J, Espinosa R, Zhao N, Pamintuan L, Till BG, Larson RA, Qian Z, Le Beau MM. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 71: 235-45. PMID 11161817 DOI: 10.1006/Geno.2000.6414  0.325
2000 Lai F, Godley LA, Fernald AA, Orelli BJ, Pamintuan L, Zhao N, Le Beau MM. cDNA cloning and genomic structure of three genes localized to human chromosome band 5q31 encoding potential nuclear proteins. Genomics. 70: 123-30. PMID 11087669 DOI: 10.1006/Geno.2000.6345  0.33
2000 Lai F, Orelli BJ, Till BG, Godley LA, Fernald AA, Pamintuan L, Le Beau MM. Molecular characterization of KLHL3, a human homologue of the Drosophila kelch gene. Genomics. 66: 65-75. PMID 10843806 DOI: 10.1006/Geno.2000.6181  0.329
1999 Godley LA, Lai F, Liu J, Zhao N, Le Beau MM. TTID: A novel gene at 5q31 encoding a protein with titin-like features. Genomics. 60: 226-33. PMID 10486214 DOI: 10.1006/Geno.1999.5912  0.342
1996 Godley LA, Kopp JB, Eckhaus M, Paglino JJ, Owens J, Varmus HE. Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes & Development. 10: 836-50. PMID 8846920 DOI: 10.1101/Gad.10.7.836  0.321
1996 Broccoli D, Godley LA, Donehower LA, Varmus HE, de Lange T. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Molecular and Cellular Biology. 16: 3765-72. PMID 8668193 DOI: 10.1128/Mcb.16.7.3765  0.302
Low-probability matches (unlikely to be authored by this person)
2012 Churpek JE, Nickels E, Marquez R, Rojek K, Liu B, Lorenz R, Lepore J, Madzo J, Wickrema A, Artz AS, van Besien K, Godley LA. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 120: 5247-9. PMID 23258901 DOI: 10.1182/Blood-2012-09-457945  0.299
2019 Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Experimental Hematology & Oncology. 8: 1. PMID 30622841 DOI: 10.1186/S40164-018-0125-6  0.298
2009 van Besien K, Kline J, Godley L, Larson R, Odenike O, Rich E, Stock W, Wickrema A, Swanson K, Horowitz S, Del Cerro P, Schroeder L, Pape L, Allen S, Artz A. Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Unexpected Renal Toxicity Biology of Blood and Marrow Transplantation. 15: 105. DOI: 10.1016/J.Bbmt.2008.12.324  0.297
2016 Churpek JE, Godley LA. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. PMID 27471235 DOI: 10.1182/Blood-2016-05-670240  0.297
2009 Zhou Y, Goodenbour JM, Godley LA, Wickrema A, Pan T. High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma. Biochemical and Biophysical Research Communications. 385: 160-4. PMID 19450555 DOI: 10.1016/J.Bbrc.2009.05.031  0.296
2014 Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, ... ... Godley LA, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3264-74. PMID 25154823 DOI: 10.1200/Jco.2014.55.2018  0.295
2015 Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Silverman LR, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kreuzer KA, Godley LA, Collins R, Atallah EL, et al. Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib. Journal of Clinical Oncology. 33: e18079-e18079. DOI: 10.1200/Jco.2015.33.15_Suppl.E18079  0.295
2011 Agarwal R, Locke FL, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley L, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins DA, White C, Artz A, Stock W. A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes Blood. 118: 496-496. DOI: 10.1182/Blood.V118.21.496.496  0.294
2007 Steensma DP, Baer MR, Slack JL, Buckstein R, Godley L, Larsen JS, Cullen MT, Kantarjian HM. Preliminary Results of a Phase II Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndrome (MDS). Blood. 110: 1450-1450. DOI: 10.1182/Blood.V110.11.1450.1450  0.294
2008 Van Besien K, Locke F, Kline J, Godley L, Larson RA, Odenike O, Rich ES, Stock W, Wickrema A, Artz A. Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase I–II Study Blood. 112: 4381-4381. DOI: 10.1182/Blood.V112.11.4381.4381  0.294
2022 Nam AS, Dusaj N, Izzo F, Murali R, Myers RM, Mouhieddine TH, Sotelo J, Benbarche S, Waarts M, Gaiti F, Tahri S, Levine R, Abdel-Wahab O, Godley LA, Chaligne R, et al. Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation. Nature Genetics. PMID 36138229 DOI: 10.1038/s41588-022-01179-9  0.294
2013 Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplantation. 48: 1437-43. PMID 23771005 DOI: 10.1038/Bmt.2013.79  0.293
2006 Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 954-64. PMID 16920562 DOI: 10.1016/J.Bbmt.2006.05.015  0.293
2007 Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, Odenike O, Pursell KJ, Larson RA, Stock W, van Besien K. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leukemia & Lymphoma. 48: 1799-805. PMID 17786717 DOI: 10.1080/10428190701534390  0.292
2009 Kenkre VP, Horowitz S, Smith SM, Artz A, Cohen KS, Godley LA, Kline J, Stock W, Besien Kv. Alemtuzumab-Containing Allogeneic Hematopoietic Cell Transplant (HCT) for Relapsed Lymphomas: Prognostic Factors and Outcome. Blood. 114: 2247-2247. DOI: 10.1182/Blood.V114.22.2247.2247  0.292
2011 Odenike O, Godley LA, Madzo J, Karrison T, Green M, Artz AS, Mattison RJ, Yee KW, Bennett M, Fulton N, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W. A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6521. PMID 28019954 DOI: 10.1200/Jco.2011.29.15_Suppl.6521  0.29
2018 Brown AL, Armstrong M, Lawrence D, Wang P, Arts P, Duployez N, Churpek J, Tawana K, Degelman E, Natsoulis G, Guzman ML, Patnaik MM, Shimamura A, Cantor AB, Ripperger T, ... ... Godley L, et al. Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB Blood. 132: 5241-5241. DOI: 10.1182/Blood-2018-99-118017  0.29
2015 Karimi YH, Jain N, Green M, Godley LA, Weiner HL, Malnassy G, Fulton N, Artz A, Liu H, Thirman MJ, Daunov M, Larson RA, Stock W, Odenike O. Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML) Blood. 126: 3777-3777. DOI: 10.1182/Blood.V126.23.3777.3777  0.288
2015 Churpek JE, Artz A, Bishop M, Liu H, Godley LA. Correspondence Regarding the Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26478096 DOI: 10.1016/J.Bbmt.2015.10.008  0.287
2020 Cavalcante de Andrade Silva M, Katsumura KR, Mehta C, Velloso EDRP, Bresnick EH, Godley LA. Breaking the spatial constraint between neighboring zinc fingers: a new germline mutation in GATA2 deficiency syndrome. Leukemia. PMID 32286542 DOI: 10.1038/S41375-020-0820-2  0.287
2009 Rich ES, Artz A, Karrison T, Godley LA, Odenike O, Joseph L, Kline J, Nguyen VH, Martinez G, del Cerro P, Pape L, Schroeder L, Allen S, Horowitz S, Cunningham J, et al. Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors. Blood. 114: 3378-3378. DOI: 10.1182/Blood.V114.22.3378.3378  0.286
2012 Richa EM, Kunnavakkam R, Godley LA, Kline J, Odenike O, Larson RA, Nguyen V, Stock W, Wickrema A, Van Besien K, Artz AS. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 14: 707-15. PMID 22548695 DOI: 10.3109/14653249.2012.681041  0.286
2011 Van Besien K, Liu H, Rich ES, Godley LA, Odenike O, Joseph L, Kline JP, Nguyen VH, Cunningham JM, Larson RA, Stock W, Wickrema A, Artz AS. Reduced intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engrafment and durable remissions. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6525. PMID 28019956 DOI: 10.1200/Jco.2011.29.15_Suppl.6525  0.286
2009 van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz AS. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leukemia & Lymphoma. 50: 1809-17. PMID 19821799 DOI: 10.3109/10428190903200790  0.286
1995 Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes & Development. 9: 882-95. PMID 7705663 DOI: 10.1101/Gad.9.7.882  0.285
2009 Kenkre VP, Horowitz S, Larson RA, Artz A, Rich ES, Zhang Y, Le Beau MM, Godley LA, Odenike O, Thirman M, van Besien K, Stock W. Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience. Blood. 114: 3395-3395. DOI: 10.1182/Blood.V114.22.3395.3395  0.284
2010 Godley LA, van Besien K. The next frontier for stem cell transplantation: finding a donor for all. Jama. 303: 1421-2. PMID 20388899 DOI: 10.1001/Jama.2010.413  0.283
2017 Guidugli L, Johnson AK, Alkorta-Aranburu G, Nelakuditi V, Arndt K, Churpek JE, Godley LA, Townsley D, Young NS, Fitzpatrick C, Del Gaudio D, Das S, Li Z. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia. PMID 28104920 DOI: 10.1038/Leu.2017.28  0.283
2007 Dinner SN, Artz A, Kocherginsky M, Ulaszek J, Pollyea D, Godley L, Larson RA, Odenike O, Rich E, Stock W, van Besien K, Wickrema A. Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT). Blood. 110: 1100-1100. DOI: 10.1182/Blood.V110.11.1100.1100  0.281
2016 Chapman CG, Mariani CJ, Wu F, Meckel K, Butun F, Chuang A, Madzo J, Bissonnette MB, Kwon JH, Godley LA. Corrigendum: TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. Scientific Reports. 6: 24963. PMID 27121680 DOI: 10.1038/Srep24963  0.281
2015 Balakrishnan KR, Whang JC, Hwang R, Hack JH, Godley LA, Sohn LL. Node-pore sensing enables label-free surface-marker profiling of single cells. Analytical Chemistry. 87: 2988-95. PMID 25625182 DOI: 10.1021/Ac504613B  0.28
2012 Godley LA. A drug that stops traffic at the nuclear border. Blood. 120: 1759-60. PMID 22936736 DOI: 10.1182/Blood-2012-07-439166  0.279
2014 Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 99: 1373-9. PMID 24816237 DOI: 10.3324/Haematol.2014.103655  0.278
2012 Muffly L, Swanson K, Boulukos M, Kocherginsky M, del Cerro P, Godley L, Kline J, Larson R, Odenike O, Pape L, Schroeder L, Stock W, Van Besien K, Artz A. Listen to Thy Patient: Poor Quality of Life (QoL) Reported by Older Adults Prior to Allogeneic Stem Cell Transplantation (allo-HCT) Is Independently Associated with Worse Transplant Outcomes Biology of Blood and Marrow Transplantation. 18: S227. DOI: 10.1016/J.Bbmt.2011.12.072  0.278
2014 Silverman LR, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg PL, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer K, Godley LA, Collins R, et al. Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs) Blood. 124: 3259-3259. DOI: 10.1182/Blood.V124.21.3259.3259  0.277
2018 Akpan IJ, Osman AEG, Drazer MW, Godley LA. Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. Current Hematologic Malignancy Reports. PMID 30259338 DOI: 10.1007/S11899-018-0473-7  0.276
2019 Brown AL, Hahn C, Hiwase D, Godley LA, Scott HS. Correct application of variant classification guidelines in germline mutated disorders to assist clinical diagnosis. Leukemia & Lymphoma. 1-2. PMID 31647332 DOI: 10.1080/10428194.2019.1680842  0.276
2016 Van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, et al. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and survival free of progression and GVHD (GRFS). Haematologica. PMID 26869630 DOI: 10.3324/Haematol.2015.138594  0.276
1995 Pinkel D, Shi Y, Gray J, Mohapatra G, Feuerstein B, Sudar D, Mullikin J, Moore D, Godley L, Varmus H, Donehower L. Analysis of DNA sequence copy number variations by comparative genomic hybridization (CGH) Cancer Genetics and Cytogenetics. 84: 138. DOI: 10.1016/0165-4608(96)85242-3  0.275
2018 Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RA. Treatment of Acute Promyelocytic Leukemia in Adults. Journal of Oncology Practice. 14: 649-657. PMID 30423270 DOI: 10.1200/Jop.18.00328  0.275
2008 Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Larsen JS, Arora S, Cullen MT, Kantarjian HM. A multicenter phase II trial of the decitabine alternative 5-day dosing regimen: Analysis of efficacy in various subgroups of patients with myelodysplastic syndromes (MDS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7032. PMID 27950008 DOI: 10.1200/Jco.2008.26.15_Suppl.7032  0.275
2014 Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg PL, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer K, Godley LA, Collins R, et al. Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs) Blood. 124: 163-163. DOI: 10.1182/Blood.V124.21.163.163  0.275
2013 Churpek JE, Lorenz R, Nedumgottil S, Onel K, Olopade OI, Sorrell A, Owen CJ, Bertuch AA, Godley LA. Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia & Lymphoma. 54: 28-35. PMID 22691122 DOI: 10.3109/10428194.2012.701738  0.274
2014 Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle J, Bishop MR, Liu H. The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago Blood. 124: 2509-2509. DOI: 10.1182/Blood.V124.21.2509.2509  0.273
2009 van Besien K, Kline J, Godley LA, Larson RA, Nguyen VH, Odenike O, Rich ES, Stock W, Wickrema A, Allen S, del Cerro P, Horowitz S, Pape L, Schroeder L, Artz A. Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes. Blood. 114: 197-197. DOI: 10.1182/Blood.V114.22.197.197  0.272
2014 D'Angelo CR, Kocherginsky M, Bishop MR, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Pisano J, Stock W, Artz A. Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA) Blood. 124: 2464-2464. DOI: 10.1182/Blood.V124.21.2464.2464  0.272
2007 Artz A, Wickrema A, Stock W, Daugherty C, Godley L, Kocherginsky M, Odenike O, Pollyea D, Rich E, Ulsazek J, Larson R, van Besien K. 223: C-reactive protein (CRP) may predict transplant-related mortality after allogeneic hematopoietic cell transplant (HCT) Biology of Blood and Marrow Transplantation. 13: 82. DOI: 10.1016/J.Bbmt.2006.12.228  0.271
2010 O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leukemia & Lymphoma. 51: 2240-9. PMID 20919852 DOI: 10.3109/10428194.2010.520773  0.271
2008 Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, et al. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Investigational New Drugs. 26: 331-8. PMID 18425419 DOI: 10.1007/S10637-008-9129-0  0.271
2008 Rich ES, Artz A, Karrison T, Wickrema A, Joseph L, Godley L, Odenike O, Kline J, Cerro Pd, Cunningham JM, Larson RA, Stock W, van Besien K. Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors Blood. 112: 3015-3015. DOI: 10.1182/Blood.V112.11.3015.3015  0.27
2015 Garcia-Manero G, Schiffer CA, Godley LA, Paquette R, Platzbecker U, Robbins PB, Norton J, Karakunnel JJ, Lindsley RC. Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps7103  0.268
2014 Muffly L, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley L, Kline J, Liu H, Odenike O, Larson R, van Besien K, Artz AS. Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients Biology of Blood and Marrow Transplantation. 20: S39-S40. DOI: 10.1016/J.Bbmt.2013.12.031  0.267
2016 Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. The Lancet. Oncology. PMID 26968357 DOI: 10.1016/S1470-2045(16)00009-7  0.267
2010 Godley LA. Donor Policies for Stem Cell Transplantation—Reply Jama. 304: 524. DOI: 10.1001/Jama.2010.1073  0.267
2016 Vasanthakumar A, Godley LA. Erratum to "5-hydroxymethylcytosine in cancer: Significance in diagnosis and therapy" [Cancer Genet 208 (2015):167-177]. Cancer Genetics. 209: 177. PMID 27085961 DOI: 10.1016/J.Cancergen.2016.02.001  0.266
2020 Roloff GW, Godley LA, Drazer MW. Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32807974 DOI: 10.1038/S41436-020-0934-Y  0.266
2006 Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplantation. 37: 307-10. PMID 16400339 DOI: 10.1038/Sj.Bmt.1705249  0.265
2017 McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nature Reviews. Cancer. 17: 513-527. PMID 28835720 DOI: 10.1038/Nrc.2017.60  0.265
2009 Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3842-8. PMID 19528372 DOI: 10.1200/Jco.2008.19.6550  0.264
2019 Applebaum MA, Barr EK, Karpus J, Nie J, Zhang Z, Armstrong AE, Uppal S, Sukhanova M, Zhang W, Chlenski A, Salwen HR, Wilkinson E, Dobratic M, Grossman R, Godley LA, et al. 5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. Jco Precision Oncology. 3. PMID 31179414 DOI: 10.1200/PO.18.00402  0.263
2015 Silverman L, Fenaux P, Al-Kali A, Baer M, Sekeres M, Roboz G, Gaidano G, Scott B, Greenberg P, Platzbecker U, Steensma D, Kambhampati S, Kreuzer K, Godley L, Collins R, et al. 88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION? Leukemia Research. 39: S44-S45. DOI: 10.1016/S0145-2126(15)30089-8  0.262
2007 Godley LA. HMGA2 levels in CML: reflective of miRNA gene regulation in a hematopoietic tumor? Leukemia & Lymphoma. 48: 1898-9. PMID 17917958 DOI: 10.1080/10428190701644348  0.261
2022 Makishima H, Bowman TV, Godley LA. DDX41-associated susceptibility to myeloid neoplasms. Blood. PMID 36455200 DOI: 10.1182/blood.2022017715  0.261
2021 Borst S, Nations CC, Klein JG, Pavani G, Maguire JA, Camire RM, Drazer MW, Godley LA, French DL, Poncz M, Gadue P. Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell model. Stem Cell Reports. PMID 34019812 DOI: 10.1016/j.stemcr.2021.04.013  0.261
2023 Godley LA. Prioritization of patients for germline testing based on tumor profiling of hematopoietic malignancies. Frontiers in Oncology. 13: 1084736. PMID 36793609 DOI: 10.3389/fonc.2023.1084736  0.259
2015 D'Angelo CR, Kocherginsky M, Pisano J, Bishop MR, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Artz AS. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leukemia & Lymphoma. 1-7. PMID 26699199 DOI: 10.3109/10428194.2015.1113279  0.256
2010 Churpek JE, Garcia JS, Madzo J, Jackson SA, Onel K, Godley LA. Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder. Leukemia & Lymphoma. 51: 1931-5. PMID 20846103 DOI: 10.3109/10428194.2010.503821  0.256
2019 Moshfegh CM, Collins CW, Gunda V, Vasanthakumar A, Cao JZ, Singh PK, Godley LA, Case AJ. Mitochondrial superoxide disrupts the metabolic and epigenetic landscape of CD4 and CD8 T-lymphocytes. Redox Biology. 101141. PMID 30819616 DOI: 10.1016/J.Redox.2019.101141  0.25
2020 Kraft IL, Godley LA. Identifying potential germline variants from sequencing hematopoietic malignancies. Hematology. American Society of Hematology. Education Program. 2020: 219-227. PMID 33275754 DOI: 10.1182/hematology.2020006910  0.25
2020 Kraft IL, Godley LA. Identifying potential germline variants from sequencing hematopoietic malignancies. Blood. 136: 2498-2506. PMID 33236764 DOI: 10.1182/blood.2020006910  0.25
2021 Feurstein S, Drazer M, Godley LA. Germline predisposition to haematopoietic malignancies. Human Molecular Genetics. PMID 34100074 DOI: 10.1093/hmg/ddab141  0.249
2019 Curran E, Bell J, Venkataraman G, Fidai S, Godley L, Kline J. Type I Interferon Signaling Predicts Inferior Survival in Patients with AML Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.07.136  0.247
2015 Silverman LR, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kreuzer KA, Godley LA, Collins R, Atallah EL, et al. Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. Journal of Clinical Oncology. 33: 7092-7092. DOI: 10.1200/Jco.2015.33.15_Suppl.7092  0.247
2013 Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2548-53. PMID 23733767 DOI: 10.1182/Blood.V118.21.3812.3812  0.244
2017 Curran E, Mattingly J, Godley L, Kline J. Role of Ddx41 in the Stimulator of Interferon Genes (STING) Pathway Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.07.251  0.241
2015 Garcia-Manero G, Fenaux P, Al-Kali A, Baer M, Sekeres M, Roboz G, Gaidano G, Scott B, Greenberg P, Platzbecker U, Steensma D, Kambhampati S, Kreuzer K, Godley L, Collins R, et al. 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS) Leukemia Research. 39: S57-S58. DOI: 10.1016/S0145-2126(15)30113-2  0.24
2009 Godley LA. Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues. Leukemia & Lymphoma. 50: 871-2. PMID 19479615 DOI: 10.1080/10428190902980889  0.239
2016 Garcia-Manero G, Al-Kali A, Baer MR, Roboz GJ, Platzbecker U, Kambhampati S, Godley LA, Collins R, Shammo JM, Santini V, Raza DA, Silverman LR, Azarnia N, Fruchtman SM, Snyder BR, et al. INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME. Journal of Clinical Oncology. 34: TPS7077-TPS7077. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps7077  0.237
2023 Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, Luskin MR, Knepper TC, Wanjari P, Wang P, Lager AM, Fitzpatrick C, Segal JP, Gharghabi M, Gurbuxani S, ... ... Godley LA, et al. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discovery. PMID 38150184 DOI: 10.1158/2643-3230.BCD-23-0106  0.236
2021 Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM, Chhetri R, Eshraghi L, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Gao S, Moore S, ... ... Godley LA, et al. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. PMID 33850299 DOI: 10.1038/s41375-021-01246-w  0.236
2022 Hains AE, Uppal S, Cao JZ, Salwen HR, Applebaum MA, Cohn SL, Godley LA. MYCN and HIF-1 directly regulate expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 1-19. PMID 35942521 DOI: 10.1080/15592294.2022.2106078  0.234
1994 Varmus HE, Godley LA, Roy S, Taylor IC, Yuschenkoff L, Shi YP, Pinkel D, Gray J, Pyle R, Aldaz CM. Defining the steps in a multistep mouse model for mammary carcinogenesis. Cold Spring Harbor Symposia On Quantitative Biology. 59: 491-9. PMID 7587104 DOI: 10.1101/Sqb.1994.059.01.054  0.223
2022 Makishima H, Saiki R, Nannya Y, Korotev SC, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, ... ... Godley LA, et al. Germline DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. PMID 36322930 DOI: 10.1182/blood.2022018221  0.221
2022 Saygin C, Roloff GW, Hahn CN, Chhetri R, Gill SI, Elmariah H, Talati C, Nunley E, Gao G, Kim A, Bishop MR, Kosuri S, Das S, Singhal D, Venugopal P, ... ... Godley LA, et al. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Advances. PMID 36001442 DOI: 10.1182/bloodadvances.2022008172  0.22
1992 Godley L, Pfeifer J, Steinhauer D, Ely B, Shaw G, Kaufmann R, Suchanek E, Pabo C, Skehel JJ, Wiley DC. Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity. Cell. 68: 635-45. PMID 1739972 DOI: 10.1016/0092-8674(92)90140-8  0.219
2019 Godley LA. Pre-MDS: CHIP, ICUS, CCUS Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.07.401  0.217
2023 Jung MM, Shen S, Botten GA, Olender T, Katsumura KR, Johnson KD, Soukup AA, Liu P, Zhang Q, Jensvold ZD, Lewis PW, Beagrie RA, Low JK, Yang L, Mackay JP, ... Godley LA, et al. Pathogenic human variant that dislocates GATA2 zinc fingers disrupts hematopoietic gene expression and signaling networks. The Journal of Clinical Investigation. PMID 36809258 DOI: 10.1172/JCI162685  0.214
2010 Van Besien K, Kline JP, Hardj M, Godley LA, Larson RA, Nguyen VH, Odenike O, Stock W, Horowitz S, Artz AS. Pharmacokinetics and assessment of renal toxicity of a clofarabine (Clo), melphalan (Mel), and alemtuzumab (Alm) conditioning regimen. Journal of Clinical Oncology. 28: 6541-6541. DOI: 10.1200/Jco.2010.28.15_Suppl.6541  0.212
2022 Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, et al. Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. Blood. PMID 36130297 DOI: 10.1182/blood.2022015853  0.211
2018 Godley LA. Debate: Should an MDS Diagnosis Still Be Mainly Based on Morphology? No! Clinical Lymphoma Myeloma and Leukemia. 18: S29. DOI: 10.1016/J.Clml.2018.06.045  0.206
2020 Trottier AM, Druhan LJ, Kraft IL, Lance A, Feurstein S, Helgeson M, Segal JP, Das S, Avalos BR, Godley LA. Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies. Blood Advances. 4: 5269-5284. PMID 33108454 DOI: 10.1182/bloodadvances.2020002013  0.204
2016 Schulze I, Rohde C, Scheller-Wendorff M, Bäumer N, Krause A, Herbst F, Riemke P, Hebestreit K, Tschanter P, Lin Q, Linhart H, Godley LA, Glimm H, Dugas M, Wagner W, et al. Increased DNA methylation of Dnmt3b targets impairs leukemogenesis Blood. 127: 1575-1586. DOI: 10.1182/blood-2015-07-655928  0.204
2021 Saygin C, Godley LA. Genetics of Myelodysplastic Syndromes. Cancers. 13. PMID 34298596 DOI: 10.3390/cancers13143380  0.203
2023 Gunn K, Myllykoski M, Cao JZ, Ahmed M, Huang B, Rouaisnel B, Diplas BH, Levitt MM, Looper R, Doench JG, Ligon KL, Kornblum HI, McBrayer SK, Yan H, Duy C, ... Godley LA, et al. (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers. Cancer Discovery. PMID 36847506 DOI: 10.1158/2159-8290.CD-22-0825  0.202
2022 Drazer MW, Homan CC, Yu K, Cavalcante de Andrade Silva M, McNeely KE, Pozsgai MJ, Acevedo-Mendez M, Segal JP, Wang P, Feng J, King S, Kim EMK, Korotev SC, Lawrence DM, Schreiber AW, ... ... Godley LA, et al. Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations. Blood Advances. PMID 35537115 DOI: 10.1182/bloodadvances.2022007211  0.201
2021 Godley LA. Germline mutations in MDS/AML predisposition disorders. Current Opinion in Hematology. 28: 86-93. PMID 33394724 DOI: 10.1097/MOH.0000000000000633  0.199
2024 Feng Q, Xu K, Shah M, Li S, Leavitt AD, Godley LA, De Smith AJ, Wiemels JL. Evaluation of the genetic basis of familial-associated early-onset hematologic cancers in an ancestral/ethnically diverse population. Haematologica. PMID 38205536 DOI: 10.3324/haematol.2023.284224  0.198
2022 Roloff GW, Drazer MW, Godley LA. Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology. Jco Precision Oncology. 5: 107-122. PMID 34994594 DOI: 10.1200/PO.20.00387  0.197
2023 Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, Arriola-Martinez LA, Pozsgai MJ, McNeely KE, Ha TT, Venugopal P, Arts P, King-Smith S, Cheah JJ, Armstrong M, Wang P, ... ... Godley LA, et al. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germ line RUNX1, GATA2, and DDX41 variants. Blood Advances. PMID 37406166 DOI: 10.1182/bloodadvances.2023010045  0.196
2022 Feurstein SK, Trottier AM, Estrada-Merly N, Pozsgai MJ, McNeely KE, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, ... ... Godley LA, et al. Germline predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. PMID 35969835 DOI: 10.1182/blood.2022015790  0.192
2023 Kraft IL, Basdag H, Koppayi A, Rodgers CV, Saygin C, Haribabu Y, Wanjari P, Niu N, Das S, de Jong JLO, Segal J, Godley LA. Sequential tumor molecular profiling identifies likely germline variants. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 101037. PMID 38054407 DOI: 10.1016/j.gim.2023.101037  0.188
2022 Osman A, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, Pozsgai MJ, Sinha E, Chandra P, Hassane DC, Sboner A, Sangani K, DiNardi N, Johnson C, Wallace SS, ... ... Godley LA, et al. Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Advances. PMID 36453641 DOI: 10.1182/bloodadvances.2022008521  0.185
2021 Cao JZ, Bigelow K, Wickrema A, Godley LA. BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines. Haematologica. PMID 34435481 DOI: 10.3324/haematol.2021.278791  0.184
2023 Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, et al. Clinical and molecular response of acute myeloid leukemia harboring non-canonical N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. PMID 36655425 DOI: 10.3324/haematol.2022.282148  0.183
2023 Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, Kenyon M, Aljurf M, Bonfim C, Makishima H, Niemeyer C, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. The Lancet. Haematology. PMID 37898151 DOI: 10.1016/S2352-3026(23)00265-X  0.182
2023 Williams LS, Williams KM, Gillis N, Bolton K, Damm F, Deuitch NT, Farhadfar N, Gergis U, Keel SB, Michelis FV, Panch SR, Porter CC, Sucheston-Campbell L, Tamari R, Stefanski HE, ... Godley LA, et al. Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant: Donor-derived malignancy and genetic risks in allo-HSCT. Transplantation and Cellular Therapy. PMID 37913908 DOI: 10.1016/j.jtct.2023.10.018  0.178
2023 Stubbins RJ, Asom AS, Wang P, Lager AM, Gary A, Godley LA. Germline loss of function and mutations and risk of hematopoietic malignancies. Haematologica. PMID 37139596 DOI: 10.3324/haematol.2022.281580  0.177
2021 Patel AA, Rojek AE, Drazer MW, Weiner H, Godley LA, Le Beau MM, Larson RA. Therapy-Related Myeloid Neoplasms in 109 Patients Following Radiation Monotherapy. Blood Advances. PMID 34492705 DOI: 10.1182/bloodadvances.2021004964  0.175
2022 Kubota Y, Zawit M, Durrani J, Shen W, Bahaj W, Kewan T, Ponvilawan B, Mori M, Meggendorfer M, Gurnari C, LaFramboise T, Feurstein S, Sekeres MA, Visconte V, Godley LA, et al. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. Leukemia. PMID 36266327 DOI: 10.1038/s41375-022-01729-4  0.175
2020 Trottier AM, Godley LA. Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. British Journal of Haematology. PMID 33615436 DOI: 10.1111/bjh.17247  0.175
2021 Patel AA, Heng J, Dworkin E, Monick S, Derman BA, DuVall AS, Gurbuxani S, Kosuri S, Liu H, Thirman M, Godley LA, Odenike O, Larson RA, Stock W. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. Ejhaem. 2: 413-420. PMID 35844676 DOI: 10.1002/jha2.224  0.159
2023 Liu J, Osman AEG, Bolton K, Godley LA. Germline predisposition to clonal hematopoiesis. Leukemia Research. 132: 107344. PMID 37421681 DOI: 10.1016/j.leukres.2023.107344  0.157
2006 Stock W, Undevia SD, Faderl S, Odenike O, Ravandi F, Verstovsek S, Rich E, Godley L, Borthakur G, Wierda W, Artz A, Bennett D, Ramirez J, Larson RA, Ratain MJ, et al. Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies. Blood. 108: 1952-1952. DOI: 10.1182/BLOOD.V108.11.1952.1952  0.156
2022 Feurstein S, Hahn CN, Mehta N, Godley LA. A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 35063349 DOI: 10.1016/j.gim.2021.12.008  0.153
2022 DeRoin L, Cavalcante de Andrade Silva M, Petras K, Arndt K, Phillips N, Wanjari P, Subramanian HP, Montes D, McElherne J, Theissen M, Briese R, Das S, Godley LA, Segal J, Del Gaudio D, et al. Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Human Mutation. PMID 35419889 DOI: 10.1002/humu.24374  0.152
2021 Pan M, Wright WC, Chapple RH, Zubair A, Sandhu M, Batchelder JE, Huddle BC, Low J, Blankenship KB, Wang Y, Gordon B, Archer P, Brady SW, Natarajan S, Posgai MJ, ... ... Godley LA, et al. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications. 12: 6468. PMID 34753908 DOI: 10.1038/s41467-021-26640-x  0.146
2022 Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Blood. PMID 35797463 DOI: 10.1182/blood.2022016867  0.142
2020 Feurstein S, Adegunsoye A, Mojsilovic D, Vij R, West DePersia AH, Rajagopal PS, Osman A, Collins RH, Kim RH, Gore SD, Greenberg P, Godley LA, Li Z, Del Gaudio D, Subramanian HP, et al. Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Advances. 4: 4873-4886. PMID 33035329 DOI: 10.1182/bloodadvances.2020001721  0.14
2021 St Martin EC, Ferrer A, Wudhikarn K, Mangaonkar A, Hogan W, Tefferi A, Gangat N, Lasho T, Altman JK, Godley LA, Patnaik MM. Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. American Journal of Hematology. PMID 34028844 DOI: 10.1002/ajh.26250  0.137
2023 Godley LA. Germ line risk variants: beyond cancer. Blood. 142: 616-617. PMID 37590029 DOI: 10.1182/blood.2023021165  0.133
2021 Feng Q, Nickels E, Muskens IS, de Smith AJ, Gauderman WJ, Yee AC, Ricker C, Mack T, Leavitt AD, Godley LA, Wiemels JL. Increased burden of familial-associated early-onset cancer risk among minority Americans compared to non-Latino Whites. Elife. 10. PMID 34155975 DOI: 10.7554/eLife.64793  0.13
2022 Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes J, Dal Cin P, DiNardo CD, Dombret H, ... ... Godley LA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. Blood. PMID 35767897 DOI: 10.1182/blood.2022015850  0.129
2021 Godley LA. Anticipation in hematopoietic malignancies: biology, bias, or both? Leukemia & Lymphoma. 1-3. PMID 34405775 DOI: 10.1080/10428194.2021.1966789  0.126
2011 Artz A, Swanson K, Kocherginsky M, Godley L, Kline J, Nguyen V, Odenike T, Stock W, Larson R, van Besien K. Features of Frailty Are Surprisingly Common in Adults 50 Years and Older Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in the Modern Era Biology of Blood and Marrow Transplantation. 17: S302. DOI: 10.1016/J.BBMT.2010.12.445  0.125
2024 Trottier AM, Feurstein S, Godley LA. Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders. Best Practice & Research. Clinical Haematology. 37: 101537. PMID 38490765 DOI: 10.1016/j.beha.2024.101537  0.12
2024 Cobaleda C, Godley LA, Nichols KE, Wlodarski MW, Sanchez-Garcia I. Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions. Cancer Discovery. 14: 396-405. PMID 38426560 DOI: 10.1158/2159-8290.CD-23-1091  0.12
2021 Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Drazer MW, Yu K, Bödör C, Cantor A, Cazzola M, Degelman E, ... ... Godley LA, et al. The RUNX1 Database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. PMID 34233450 DOI: 10.3324/haematol.2021.278762  0.087
2022 Niemeyer CM, Rudelius M, Shimamura A, Flotho C, Hasle H, Stieglitz E, Strahm B, Godley LA, Weinberg OK, Orazi A, Calvo KR. Classification of rare pediatric myeloid neoplasia-Quo vadis? Leukemia. PMID 36271151 DOI: 10.1038/s41375-022-01731-w  0.078
2021 Feurstein S, Churpek JE, Walsh T, Keel S, Hakkarainen M, Schroeder T, Germing U, Geyh S, Heuser M, Thol F, Pohlkamp C, Haferlach T, Gao J, Owen C, Goehring G, ... ... Godley LA, et al. Germline variants drive myelodysplastic syndrome in young adults. Leukemia. PMID 33510405 DOI: 10.1038/s41375-021-01137-0  0.077
2023 Saheb Kashaf S, Godley LA, Chadha A, Waldinger JB. Systemic mastocytosis, in the context of a deleterious germline variant, treated with ripretinib. Jaad Case Reports. 37: 119-122. PMID 37405177 DOI: 10.1016/j.jdcr.2023.04.007  0.069
2022 Feurstein SK, Luo X, Shah M, Walker T, Mehta N, Wu D, Godley LA. Revision of RUNX1 Variant Curation Rules. Blood Advances. PMID 35764482 DOI: 10.1182/bloodadvances.2022008017  0.052
2004 Alberts DS, Godley L. Clinical Trials and End-of-Life Decision Making. The Virtual Mentor : Vm. 6. PMID 23260203 DOI: 10.1001/virtualmentor.2004.6.11.ccas1-0411  0.017
Hide low-probability matches.